胃癌术后辅助治疗方案Ⅲ
方案评价
续表
点评
XP方案联合放疗目前可用于胃癌D2术后患者的辅助治疗，尤其是Ⅰb～Ⅳ（M0）期胃癌D2术后，淋巴结阳性比＞25%及肠型胃癌患者中。该ARTIST研究（NCT00411229）是由韩国研究者发起的Ⅲ期随机对照试验，旨在比较Ⅰb～Ⅳ（M0）期胃癌D2术后辅助放化疗（卡培他滨+顺铂+RT）的有效性和安全性，与单纯辅助XP的患者相比，胃癌D2术后的同步放化疗较单纯化疗不能改善DFS和OS，但是有淋巴结转移（淋巴结清扫比率＞25%）及肠型胃癌患者中有潜在获益的可能。
（张 涛 于丹丹）
参考文献
［1］ YU JI，LIM DH，AHN YC，et al.Effects of adjuvant radiotherapy on completely resected gastric cancer:A radiation oncologist's view of the ARTIST randomized phaseⅢ trial.Radiotherapy and Oncology，2015，117:171-177.
［2］ KIM Y，PARK SH，KIM K-M，et al.The influence of metastatic lymph node ratio on the treatment outcomes in the adjuvant chemoradiotherapy in stomach tumors（ARTIST）trial:A phaseⅢ trial.Journal of Gastric Cancer，2016，16:105-110.
［3］ LEE J，LIM DH，KIM S，et al.Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:The ARTIST trial.J Clin Oncol，2012，30:268-273.
［4］ PARK S，SOHN TS，LEE J，et al.Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer:final report of the adjuvant chemoradiotherapy in stomach tumors trial，including survival and subset analyses.J Clin Oncol，2015，33:3130-3136.